I期临床-话题@MedSci

#I期临床#

570篇内容 | 7053人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652928, encodeId=63ae165292826, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始, objectType=article, longId=178054, objectId=7b581e8054f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b581e8054f4, replyNumber=0, likeNumber=123, createdTime=2019-12-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b581e8054f4, moduleTitle=BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b581e8054f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652977, encodeId=61a416529e7b9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, objectType=article, longId=185945, objectId=1f6e1859452d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6e1859452d, replyNumber=0, likeNumber=70, createdTime=2020-07-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6e1859452d, moduleTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6e1859452d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652962, encodeId=9c751652962fc, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, objectType=article, longId=184287, objectId=1a1218428e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a1218428e0d, replyNumber=0, likeNumber=75, createdTime=2020-05-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a1218428e0d, moduleTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a1218428e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653057, encodeId=1cf0165305e0a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功, objectType=article, longId=197879, objectId=2bb519e879bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bb519e879bc, replyNumber=0, likeNumber=68, createdTime=2021-01-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bb519e879bc, moduleTitle=右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bb519e879bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652931, encodeId=d56b165293192, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=罗氏Xofluza作为预防性流感药物III期临床安全有效, objectType=article, longId=178688, objectId=6d301e8688c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d301e8688c1, replyNumber=0, likeNumber=81, createdTime=2020-02-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d301e8688c1, moduleTitle=罗氏Xofluza作为预防性流感药物III期临床安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d301e8688c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652964, encodeId=d654165296481, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究, objectType=article, longId=184532, objectId=4163184532b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4163184532b0, replyNumber=0, likeNumber=79, createdTime=2020-11-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4163184532b0, moduleTitle=Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4163184532b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652967, encodeId=f1e3165296e86, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, objectType=article, longId=184902, objectId=8f0518490243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0518490243, replyNumber=0, likeNumber=76, createdTime=2020-05-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0518490243, moduleTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f0518490243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652989, encodeId=cf57165298939, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, objectType=article, longId=187677, objectId=e89218e67760, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e89218e67760, replyNumber=0, likeNumber=59, createdTime=2020-12-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e89218e67760, moduleTitle=芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e89218e67760)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653003, encodeId=0d7a16530035c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=20价肺炎球菌结合疫苗（20vPnC）的III期临床结果, objectType=article, longId=190431, objectId=604619043165, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=604619043165, replyNumber=0, likeNumber=43, createdTime=2020-06-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=604619043165, moduleTitle=20价肺炎球菌结合疫苗（20vPnC）的III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=604619043165)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652972, encodeId=460316529e2f1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验, objectType=article, longId=185521, objectId=11cc18552145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11cc18552145, replyNumber=0, likeNumber=59, createdTime=2020-12-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11cc18552145, moduleTitle=HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11cc18552145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652930, encodeId=144b1652930ec, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, objectType=article, longId=178245, objectId=e1fa1e8245bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fa1e8245bc, replyNumber=0, likeNumber=55, createdTime=2020-07-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fa1e8245bc, moduleTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fa1e8245bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652982, encodeId=95cd1652982d8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果, objectType=article, longId=186746, objectId=f965186e4626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f965186e4626, replyNumber=0, likeNumber=90, createdTime=2020-02-03, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f965186e4626, moduleTitle=卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f965186e4626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652959, encodeId=defe1652959bd, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=71, createdTime=2020-07-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652974, encodeId=8a0116529e459, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, objectType=article, longId=185534, objectId=9c1618553426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1618553426, replyNumber=0, likeNumber=59, createdTime=2020-08-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1618553426, moduleTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1618553426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652975, encodeId=595516529e5ee, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=91, createdTime=2020-05-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652971, encodeId=f59d16529e1a4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, objectType=article, longId=185461, objectId=e368185461fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368185461fe, replyNumber=0, likeNumber=60, createdTime=2020-02-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368185461fe, moduleTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368185461fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652917, encodeId=2440165291e7f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, objectType=article, longId=175613, objectId=674d1e56136b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=674d1e56136b, replyNumber=0, likeNumber=72, createdTime=2020-01-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=674d1e56136b, moduleTitle=2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=674d1e56136b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653006, encodeId=dac11653006eb, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Losmapimod治疗面肩胛肱型肌营养不良症的I期临床试验取得积极结果, objectType=article, longId=190847, objectId=dcd819084eb8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcd819084eb8, replyNumber=0, likeNumber=64, createdTime=2021-01-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcd819084eb8, moduleTitle=Losmapimod治疗面肩胛肱型肌营养不良症的I期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcd819084eb8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652912, encodeId=e51d165291231, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, objectType=article, longId=174669, objectId=3b101e46693f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b101e46693f, replyNumber=0, likeNumber=87, createdTime=2020-03-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b101e46693f, moduleTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b101e46693f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652925, encodeId=578c16529256b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=77, createdTime=2019-11-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始

2019-12-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功

2020-07-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功

2020-05-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

右美托咪定舌下薄膜BXCL501治疗精神分裂症：III期临床成功

2021-01-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

罗氏Xofluza作为预防性流感药物III期临床安全有效

2020-02-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Rheumato：非甾体选择性糖皮质激素受体调节剂AZD9567I期临床研究

2020-11-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant

2020-05-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

芬氟拉明治疗Lennox-Gastaut综合征的III期临床试验取得积极结果

2020-12-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

20价肺炎球菌结合疫苗（20vPnC）的III期临床结果

2020-06-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验

2020-12-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功

2020-07-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果

2020-02-03

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2020-07-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功

2020-08-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-05-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2020-02-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019年国际血栓和止血学会：II期临床试验抗组织因子抑制剂单抗Concizumab对A/B型血友病患者安全有效

2020-01-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Losmapimod治疗面肩胛肱型肌营养不良症的I期临床试验取得积极结果

2021-01-13

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

2020-03-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2019-11-15

科室
- - 订阅+
  - 更多科室
工具
服务